Riskpilot← Back to searchSign inGet full accessRx Läkarkonsult AB
ABActiveOrg 5592259039Parkgatan 14General medical practice activities · NACE 8621Est. 20191 employees
Revenue 2025
SEK 427K
+90% vs 2024
EBITDA margin
48.5%
+85% vs 2024
Equity ratio
66.7%
Financial strength
Net profit 2025
SEK 163K
+96% vs 2024
| Revenue | SEK 427K | +90% |
| EBITDA | SEK 207K | +85% |
| Net profit | SEK 163K | +96% |
| Total assets | SEK 336K | +52% |
| Equity | SEK 224K | +39% |
| Employees | 1 | — |
Legal name
Rx Läkarkonsult AB
Org number
5592259039
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
8 november 2019
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-03-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget skall bedriva medicinsk verksamhet inom hälso och skönhetsvård, forskning, utbildning och konsultverksamhet samt import och export av medicinsk utrustning ävensom handel och förvaltning av värdepapper fast och lös egendom, och därmed förenlig verksamhet.
Address
Parkgatan 14
Email
egill.arnljots@live.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 168 | 249 | 134 | 225 | 427 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −4 | 91 | 12 | 112 | 207 |
| Depreciation & amort. | −0 | −4 | −7 | −7 | −7 |
| EBIT | −4 | 87 | 5 | 105 | 200 |
| Net financials | — | −1 | — | — | 1 |
| Profit before tax | −4 | 86 | 5 | 105 | 201 |
| Tax | −0 | −20 | −1 | −22 | −38 |
| Net profit | −4 | 66 | 4 | 83 | 163 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 182 | 171 | 118 | 221 | 336 |
| Equity | 48 | 115 | 78 | 161 | 224 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 134 | 56 | 39 | 60 | 112 |
| Total debt | 134 | 56 | 39 | 60 | 112 |
EBITDA margin
48.5%
This company
15.8%
Market median
+207% vs market
20212025
Equity ratio
66.7%
This company
38.2%
Market median
+75% vs market
20212025
Return on equity
72.8%
This company
18.4%
Market median
+296% vs market
20212025
Net profit margin
38.2%
This company
8.1%
Market median
+372% vs market
20212025
Asset turnover
1.27×
This company
1.12×
Market median
+13% vs market
20212025
Debt / equity
0.50×
This company
0.62×
Market median
+19% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-04-01 – 2025-03-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-04-01 – 2024-03-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-04-01 – 2023-03-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-04-01 – 2022-03-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-04-01 – 2021-03-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Rx Läkarkonsult AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Rebeka Arnljots | Board of Directors | 0 companies |
| Egill Snaebjörnsson Arnljots | Deputy Board Member | 0 companies |